Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers

• Matthieu Dusselier ,

  Roles Conceptualization, Investigation, Writing – original draft

  * E-mail: matthieu.dusselier@gmail.com

  Affiliation Service de Pneumologie, CHU, Limoges, France

  http://orcid.org/0000-0001-5421-7254

  ⨯
• Elise Deluche,

  Roles Project administration

  Affiliation Service d’Oncologie Médicale, CHU, Limoges, France

  ⨯
• Nellie Delacourt,

  Roles Writing – review & editing

  Affiliation Service de Pneumologie, CHU, Limoges, France

  ⨯
• Julia Ballouhey,

  Roles Writing – review & editing

  Affiliation Service de Pneumologie, CHU, Limoges, France

  ⨯
• Thomas Egenod,

  Roles Resources

  Affiliation Service de Pneumologie, CHU, Limoges, France

  ⨯
• Boris Melloni,

  Roles Writing – review & editing

  Affiliation Service de Pneumologie, CHU, Limoges, France

  ⨯
• Charlotte Vergnenègre,

  Roles Resources, Writing – review & editing

  Affiliation CHU Bordeaux, service des maladies respiratoires, Bordeaux, France

  ⨯
• Rémi Veillon,

  Roles Resources

  Affiliation CHU Bordeaux, service des maladies respiratoires, Bordeaux, France

  ⨯
• Alain Vergnenègre

  Roles Investigation, Supervision

  Affiliation Service de Pneumologie, CHU, Limoges, France

  ⨯